2020
DOI: 10.1007/s11695-020-05118-7
|View full text |Cite
|
Sign up to set email alerts
|

Are We Ready for Bariatric Surgery in a Liver Transplant Program? A Meta-Analysis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
11
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 18 publications
(11 citation statements)
references
References 53 publications
0
11
0
Order By: Relevance
“…Based on this latter finding, although there is no consensus yet, the approach that is currently best accepted is to perform LT first and bariatric surgery later on [ 98 , 99 ].…”
Section: Bariatric Surgery and Liver Transplantmentioning
confidence: 99%
“…Based on this latter finding, although there is no consensus yet, the approach that is currently best accepted is to perform LT first and bariatric surgery later on [ 98 , 99 ].…”
Section: Bariatric Surgery and Liver Transplantmentioning
confidence: 99%
“…A chronic, silent, obesity-related disease, such as NAFLD, affects mostly patients with a higher BMI, higher prevalence of T2DM, metabolic comorbidities, lower glomerular filtration rate, and most of all, old patients: this represents a consistent problem on LT waiting lists and the patient management before and after the LT [144,[150][151][152].…”
Section: Timing Of Bariatric Surgery and Effects Of Nafld On The Waiting List For Ltmentioning
confidence: 99%
“…BS after LT aims to treat morbid obesity in efforts to reduce the risk of metabolic complications after LT and improving long-term outcomes. Reported series described an interval from LT to BS ranging between 27 and 70 months, 44 45 and thus the safety and effectiveness of BS within the first 2 years of transplant are unknown. Special care with respect to immunosuppression should be taken on planning BS after LT, with restrictive procedures having less effect on absorption than malabsorptive procedures (which may require more careful immunosuppression follow-up).…”
Section: Bariatric Surgery and Liver Transplantationmentioning
confidence: 99%
“…Taken together, however, published data suggest that BS does not significantly alter immunosuppression levels and doses. 45 As with any surgical procedure, patients on mammalian target of rapamycin inhibitors (mTOR inhibitors) would need to be switched to other immunosuppression regimens, 46 due to the high risk of wound complications in patients on these drugs.…”
Section: Bariatric Surgery and Liver Transplantationmentioning
confidence: 99%